Humanigen Inc. (HGEN) Prices 5M Share Common Offering at $18.50/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
Humanigen Inc. (HGEN) Announces Proposed Public Offering of 5M Shares of Common Stock
March 29, 2021 4:11 PM EDTHumanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumabTM, today announced that it has commenced an underwritten public offering 5,000,000 shares of its common stock. In connection with this... More
Pre-Open Stock Movers 03/29: (HGEN) (FLY) (HMHC) Higher; (ORPH) (NMR) (CS) Lower (more...)
March 29, 2021 9:29 AM EDTToday's Pre-Open Stock Movers:
Humanigen, Inc. (Nasdaq: HGEN) 65.3% HIGHER; announced positive topline results from its Phase 3 clinical trial evaluating the efficacy and safety of lenzilumab in patients hospitalized with COVID-19. Trial results showed that patients who received lenzilumab and other treatments, including steroids and/or remdesivir, had a 54% greater relative likelihood of survival without the need for IMV compared with patients receiving placebo and other treatments. These results are statistically significant.
Humanigen Inc. (HGEN) Reports Positive Phase 3 Topline Results Demonstrating That Lenzilumab Improves Survival Without Need for Mechanical Ventilation in Hospitalized Patients With COVID-19
March 29, 2021 7:06 AM EDTHumanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumab, today announced positive topline results from its Phase 3 clinical trial evaluating the efficacy and safety of lenzilumab in patients hospitalized with COVID-19. Trial results showed that patients who received lenzilumab and other treatments, including steroids and/or remdesivir, had a 54% greater relative likelihood of survival without the need for IMV compared with patients receiving placebo and other treatments. These results are statistically significant.
The results from our Phase 3 clinical... More
